0R15 8540.2617 2.2296% 0R1E 8262.0176 -1.9229% 0M69 17217.5293 36.7556% 0R2V 181.94 0.1872% 0QYR 1423.1256 0.3538% 0QYP 402.3999 -0.7645% 0LCV 126.7 -1.0156% 0RUK 2959.3132 1.277% 0RYA 1718.0 -0.0582% 0RIH 142.0 0.3534% 0RIH 140.48 -1.0704% 0R1O 167.0 9767.0606% 0R1O None None% 0QFP 9785.8682 94.1641% 0M2Z 268.7914 -0.0683% 0VSO 22.315 -37.3262% 0R1I None None% 0QZI 477.0 0.5269% 0QZ0 220.0 0.0% 0NZF 818.1412 64.1535%

Kiniksa Pharmaceuticals Ltd

Healthcare US KNSA


Last update at 2024-02-20T20:50:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 11.03M -156.53900M -156.22900M -163.91400M -103.44100M
Minority interest - - - - -
Net income 183.36M -157.92400M -161.38100M -161.86700M -103.22700M
Selling general administrative 97.95M 85.95M 45.32M 34.96M 21.56M
Selling and marketing expenses - - - - -
Gross profit 173.21M 29.44M - - 0.00000M
Reconciled depreciation 2.40M 2.35M 2.40M 2.07M 0.29M
Ebit 7.37M -158.99100M -159.76800M -172.03100M -108.44600M
Ebitda 9.77M -156.63600M -157.36300M -169.96300M -108.16000M
Depreciation and amortization 2.40M 2.35M 2.40M 2.07M 0.29M
Non operating income net other 1.25M 0.10M 1.13M 6.05M 4.72M
Operating income 7.37M -156.63600M -157.36300M -169.96300M -108.16000M
Other operating expenses 210.41M 195.18M 157.36M 169.96M 108.16M
Interest expense 1.25M 2.45M 3.54M 8.12M 0.00000M
Tax provision -172.33700M 1.39M 5.15M -2.04700M -0.21400M
Interest income 1.25M 0.10M 1.13M 6.05M 4.72M
Net interest income 1.25M 0.10M 1.13M 6.05M 4.72M
Extraordinary items - - - - -
Non recurring - 0.83M - - -
Other items - - - - -
Income tax expense -172.33700M 1.39M 5.15M -2.04700M -0.21400M
Total revenue 220.18M 38.54M 0.00000M 0.00000M 0.00000M
Total operating expenses 163.44M 186.08M 157.36M 169.96M 108.16M
Cost of revenue 46.97M 9.10M - - 0.00000M
Total other income expense net 3.65M 0.10M 1.13M 6.05M 4.72M
Discontinued operations - - - - -
Net income from continuing ops 183.36M -157.92400M -161.38100M -161.86700M -103.22700M
Net income applicable to common shares 183.36M -157.92400M -161.38100M -161.86700M -103.22700M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 459.67M 232.80M 349.46M 254.53M 321.96M
Intangible assets 18.25M 19.25M - - -
Earning assets - - - - -
Other current assets 10.54M 6.58M 9.56M 8.25M 6.45M
Total liab 63.52M 47.76M 37.53M 29.11M 42.70M
Total stockholder equity -492.03400M -675.39700M -517.47300M -356.09200M -194.22500M
Deferred long term liab - - - - 0.43M
Other current liab 23.87M 1.54M 0.04M 0.03M 31.64M
Common stock 0.02M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.01M 0.01M
Retained earnings -492.03400M -675.39700M -517.47300M -356.09200M -194.22500M
Other liab 13.84M 0.27M 0.81M 0.33M 0.14M
Good will - - - - -
Other assets 191.32M 8.72M 12.16M 4.58M 1.86M
Cash 122.72M 122.47M 114.04M 46.93M 307.30M
Cash and equivalents - - - - -
Total current liabilities 47.07M 44.82M 31.85M 27.83M 42.55M
Current deferred revenue 12.00M 38.03M 29.20M 20.41M -
Net debt -116.79600M -116.42000M -107.05300M -44.27600M -307.30400M
Short term debt 3.30M 3.38M 2.11M 1.70M -
Short long term debt - - - - -
Short long term debt total 5.92M 6.05M 6.99M 2.65M -
Other stockholder equity -0.06300M 0.05M 0.02M -0.04800M -0.00900M
Property plant equipment 1.66M 2.83M 4.05M 8.32M 6.36M
Total current assets 243.06M 196.45M 333.25M 241.63M 313.75M
Long term investments - - - - -
Net tangible assets 377.90M 194.55M 311.94M 225.42M 279.27M
Short term investments 67.89M 59.73M 209.44M 186.45M 235.33M
Net receivables 20.32M 3.98M - - -
Long term debt - - - - -
Inventory 21.60M 3.67M - - -
Accounts payable 7.90M 1.87M 0.50M 5.69M 10.92M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.04M -0.06600M -0.03400M 0.03M -0.00400M
Additional paid in capital - - - - -
Common stock total equity 0.02M 0.02M 0.02M 0.01M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity -492.03400M -675.39700M -517.47300M -356.09200M -194.22500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.82M 8.72M 5.59M 0.21M 0.64M
Deferred long term asset charges - - - - 1.65M
Non current assets total 216.61M 36.35M 16.21M 12.91M 8.21M
Capital lease obligations 5.92M 6.05M 6.99M 2.65M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -8.06400M 149.05M -23.16100M 52.42M -233.90800M
Change to liabilities 15.89M 11.17M 4.31M 0.26M 18.12M
Total cashflows from investing activities -8.07800M 128.63M -23.44400M 49.21M -239.19800M
Net borrowings - - - - -
Total cash from financing activities 2.52M 5.88M 227.09M 84.11M 346.74M
Change to operating activities -6.35100M 6.91M 0.65M -12.32000M 9.51M
Net income 183.36M -157.92400M -161.38100M -161.86700M -103.22700M
Change in cash 0.24M 8.22M 67.11M -25.04800M 26.53M
Begin period cash flow 122.47M 114.25M 47.14M 72.19M 45.66M
End period cash flow 122.72M 122.47M 114.25M 47.14M 72.19M
Total cash from operating activities 5.81M -126.29800M -136.53200M -158.36900M -81.01200M
Issuance of capital stock 3.42M 0.00000M 221.67M 83.11M 350.02M
Depreciation 2.40M 2.35M 2.40M 2.07M 0.29M
Other cashflows from investing activities 0.09M -20.00000M - 52.42M -233.90800M
Dividends paid - - - - -
Change to inventory -17.92400M -3.67500M -3.67500M -3.67500M -3.67500M
Change to account receivables -8.67500M -3.91000M -3.91000M -3.91000M -3.91000M
Sale purchase of stock -0.90100M 5.88M 6.55M 84.22M 350.39M
Other cashflows from financing activities -8.07800M 128.63M -1.13600M 1.00M 187.54M
Change to netincome -160.34200M 25.29M 25.24M 11.95M 4.79M
Capital expenditures 0.10M 20.41M 0.28M 3.20M 5.29M
Change receivables -8.67500M -3.91000M - - -
Cash flows other operating -8.82600M -0.26500M -7.22100M -7.27300M 0.44M
Exchange rate changes - - - - -
Cash and cash equivalents changes 0.24M 8.22M 67.11M -25.04800M 26.53M
Change in working capital -22.57500M 0.69M -4.31500M -17.02500M 18.33M
Stock based compensation 25.12M 25.17M 20.88M 15.08M 5.70M
Other non cash items 2.99M 3.40M 1.52M 6.53M -1.12200M
Free cash flow 5.70M -146.71300M -136.81500M -161.57200M -86.30200M


  • Previous Close 19.94
  • Market Cap1266.79M
  • Volume107892
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-16.82700M
  • Revenue TTM248.75M
  • Revenue Per Share TTM3.56
  • Gross Profit TTM 173.21M
  • Diluted EPS TTM-0.11

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Kiniksa Pharmaceuticals Ltd
-0.05 0.25% 19.89 0.0 0.0 5.04 3.10 4.29 -63.4349
Novo Nordisk A/S
-2.535 2.04% 121.47 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
-2.69 2.16% 121.65 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
-2.501 0.59% 419.70 30.40 24.75 10.68 6.25 9.52 20.36
-0.18 0.19% 92.43 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals Ltd

Clarendon House, Hamilton, Bermuda, HM 11

Key Executives

Name Title Year Born
Mr. Sanj K. Patel CEO & Chairman 1970
Dr. John F. Paolini Sr. VP & Chief Medical Officer 1965
Mr. Mark Ragosa C.F.A. Sr. VP & CFO 1975
Mr. Eben Tessari Sr. VP & COO 1982
Mr. Michael R. Megna CPA Chief Accounting Officer & Group VP of Fin. 1971
Ms. Mei Jang Sr. VP of Technical Operations NA
Rachel Frank Associate Director of Investor Relations NA
Mr. Chad Morin Sr. VP & Chief Compliance Officer NA
Ms. Madelyn Zeylikman SVP, Gen. Counsel & Sec. NA
Ms. Melissa Manno Sr. VP & Chief HR Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions